



Patents

From foundational patents to delivery technology, we have pioneered the development of mRNA medicine since our founding. Along the way, we have accumulated a broad collection of patents, with several hundred additional pending patent applications.

Intellectual Property

The following articles are protected by the following United States patents for Moderna Inc.

Spikevax™ (mRNA-1273 COVID-19 VACCINE)

[US 11,622,972](#)

[US 11,524,023](#)

[US 11,485,972](#)

[US 10,898,574](#)

[US 10,703,789](#)

[US 10,702,600](#)

[US 10,577,403](#)

[US 10,442,756](#)

[US 10,266,485](#)

[US 10,064,959](#)

[US 9,868,692](#)

In addition, Moderna Inc. owns additional patents in the United States and foreign jurisdictions.

Investors

[Investors overview](#) 

Newsroom

[News and media 2023](#)

[Media kit](#)

Patents

Patents

Media Center

All media

Blogs

Videos

Podcasts

Partnerships

Strategic collaborators

Careers

Life at Moderna

People behind the science

Awards

Join our team 

Innovation Incubator

New Venture Labs



[Terms of use](#)

[Privacy statement](#)

[Cookie Statement](#)

[Contact Moderna](#)

[Sitemap](#)

© 2023 Moderna, Inc.